サンプル依頼リスト カート
  • English
  • Korean
表紙：HIV関連リポジストロフィーの世界市場-2023年～2030年
市場調査レポート
商品コード
1345415

HIV関連リポジストロフィーの世界市場-2023年～2030年

Global HIV-associated Lipodystrophy Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 186 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
HIV関連リポジストロフィーの世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 186 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

HIV関連リポジストロフィーの世界市場は、2022年に1億7,490万米ドルに達し、2030年には2億2,811万米ドルに達すると予測され、予測期間2023-2030年のCAGRは3.4%で成長する見込みです。

リポジストロフィーとは、HIV感染者の一部に起こりうる体脂肪の変化を指します。リポジストロフィーには、体脂肪の蓄積、体脂肪の喪失、またはその両方があります。リポジストロフィーは、HIV感染やHIV治療薬によるものかもしれないが、その正確な理由はわかっていません。最新のHIV治療薬は、過去に開発されたHIV治療薬と比較して、リポジストロフィーを誘発する可能性は低いです。

最新のHIV治療薬はリポジストロフィーを引き起こす可能性が低いため、現在HIV治療を開始する大多数の人にとって、リポジストロフィーは問題ではありません。この症候群は2つの異なる臨床症状を構成し、時に同時に現れることがあります。この疾患によって患者が遭遇する可能性のある罹患率を減少させるために、いくつかの代替療法が指定されています。

HIV感染症例の増加、認知を広めるためのイニシアチブの増加、支援活動などが、予測期間中の世界のHIV関連リポジストロフィー市場の成長を後押しすると予想されます。さらに、研究活動の増加とHIV研究への資金提供は、予測期間中の世界のHIV関連リポジストロフィー市場の成長に貢献すると予想されます。

ダイナミクス

HIV有病率の増加が市場成長を牽引

HALSの有病率は、高活性抗レトロウイルス療法（HAART）曝露期間の拡大とともに上昇し、抗ウイルス療法を受けている人の約50％に認められると報告されています。しかし、HIV関連リポジストロフィーの正確な有病率は、症例の定義が異なるために確立することは困難ですが、世界中のHIV感染者の10％から80％と推定されています。したがって、HIV感染症例の増加は、予測期間中の世界のHIV関連リポジストロフィー市場の成長を後押しすると推定されます。

例えば、国連HIV/エイズ合同計画（UNAIDS）によると、2022年には世界で3,900万人以上がHIVに感染し、130万人以上が新たにHIVに感染し、約630,000人がエイズ関連疾患のために死亡しました。さらに、同じ情報源によると、2022年には約2,980万人のエイズ患者が抗レトロウイルス療法を受け、合計8,560万人がHIVに感染し、流行開始以来、エイズ関連の病気で4,040万人が死亡しています。

HIVの負荷と闘うイニシアチブの増加

HIV感染症やそれに関連する死亡者数の増加に対抗するための各国政府の取り組みが増加していることも、世界市場の成長に寄与しています。例えば、2023年5月、国家HIV/AIDS戦略および米国におけるHIV流行終結イニシアティブは、できるだけ早く人々を検出することを強調し、スティグマ、差別などを含む幅広い社会的、経済的、人口統計学的側面のために感染の可能性が向上した住民の要求を十分に満たすために、かなりのHIV検査方法の利用可能性を確認しました。

また、安定した住居はHIV/AIDSと共に生きる個人の幸福に不可欠であり、より良い健康効果と感染の減少に影響を与えることが研究によって示されているため、米国住宅都市開発省（HUD）のHIV/AIDS住宅局は、2022年12月にテナントベースの賃貸サービス、立証支援、および追加の宿泊施設の活動を支援するエイズ患者のための住宅機会（HOPWA）恒久的な支援住宅（PSH）の更新および交換補助金で1,300万米ドル以上を宣言しました。

HIV関連リポジストロフィー治療の多額の費用

HIV関連リポジストロフィー治療には多額の費用がかかるため、予測期間中のHIV関連リポジストロフィー市場の成長は妨げられると予想されます。例えば、Sculptra（注射用ポリL乳酸、New-Fill）療法は、米国で認可されたHIV関連脂肪萎縮症のための最も主要な顔面充填剤であり、米国では、麻酔や手術施設の費用を除いて、1バイアル当たりおよそ500米ドルから1,000米ドルかかります。ラディエッセ（カルシウムヒドロキシルアパタイト）もまた、HIV感染者の顔面脂肪萎縮症に対してFDAの認可を受けています。

ラディエッセには、骨や歯から発見された、体内でのコラーゲン産生を促進する物質である合成カルシウムハイドロキシルアパタイトが含まれており、米国では1バイアルあたり約600～800米ドルします。同様に、「脂肪移植」や「脂肪移植」とも呼ばれる自己脂肪移植法は数千米ドル、コラーゲン（コスモダーム、コスモプラスト）は米国での1回あたりの治療費は300～900米ドルで、治療期間は3～6カ月で、繰り返し行う必要があります。

HIV抗レトロウイルス療法におけるギャップ

HIVのART治療における格差も、予測期間中の世界市場の成長を鈍化させると予想されます。例えば、2015年、世界保健機関（WHO）は、多国間のHIV政策を修正し、抗レトロウイルス療法（ART）開始のためのCD4ベースの臨床病期分類を撤回し、小児のART適格性を拡大する「Treat All」政策を承認しました。

「Treat All」政策では、HIV治療における公平性の向上が求められたが、2010年から2020年の間に、小児のART適用範囲は3倍に拡大し、16％から54％に急増しました。しかし、小児のART普及率は、2010年の26％から2020年には74％に急増した成人のART普及率に比べ、常に這い上がっています。一方、エイズ関連の死傷者は10年間で24万人から9万9,000人へと半減しました。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • HIV罹患率の増加が市場成長を牽引
      • HIVの蔓延に対する取り組みの増加
    • 抑制要因
      • HIV関連リポジストロフィー治療の多額の費用
      • HIV抗レトロウイルス療法におけるギャップ
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • 特許分析
  • 流通チャネル動向
  • SWOT分析
  • DMIの見解

第6章 COVID-19分析

第7章 タイプ別

  • 薬物治療
    • 同化調節薬
    • 成長ホルモン
    • 同化ステロイド
    • メトホルミン
    • チアゾリジン系薬剤
    • その他
  • 美容矯正治療
    • 脂肪療法
    • 脂肪吸着
    • 皮膚フィラー
    • 自家脂肪移植
    • その他

第8章 投与経路別

  • 眼科経口剤
  • 注射剤
  • その他

第9章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Theratechnologies Inc
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Amryt Pharmaceuticals, Inc.
  • Fawn Incorporation
  • Abbott Healthcare Solutions
  • Lupin Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Bayer Inc.
  • Novartis Pharmaceuticals Corporation
  • AstraZeneca
  • GlaxoSmithKline
  • AbbVie
  • Galderma Laboratories, L.P.

第13章 付録

目次
Product Code: PH6768

Overview

Global HIV-associated Lipodystrophy Market reached US$ 174.90 million in 2022 and is expected to reach US$ 228.11 million by 2030, growing with a CAGR of 3.4% during the forecast period 2023-2030.

Lipodystrophy refers to the transformations in body fat that can impact some individuals with HIV. Lipodystrophy can have a buildup of body fat, loss of body fat, or both. Lipodystrophy may be owing to HIV infection or drugs utilized for the treatment of HIV, but its exact reason is not comprehended. The most recent HIV drugs are less likely to induce lipodystrophy compared to HIV medications designed in the past.

Lipodystrophy is not a problem for a majority of individuals who begin HIV therapy currently, because newer HIV medicines are less likely to cause lipodystrophy. The syndrome constitutes two different clinical indications that can occasionally emerge concurrently. Several therapy alternatives have been specified to aid in reducing the morbidity patients may encounter due to this disorder.

The growing cases of HIV infections, increasing initiatives to spread awareness, and support efforts among other factors are expected to boost the global HIV-associated lipodystrophy market growth during the forecast period. Further, increasing research activities and HIV research funding are expected to contribute to the global HIV-associated lipodystrophy market growth during the forecast period.

Dynamics

The Growing Prevalence of HIV Drive the Market Growth

The preponderance of HALS rises with expanded periods of exposure to highly active antiretroviral therapy (HAART) and is registered to be present in around 50% of individuals on antiviral therapy. However, the exact prevalence of HIV-associated lipodystrophy has been challenging to establish due to differences in case definition, but estimates range from 10% to 80% among all people living with HIV worldwide. Thus, the growing cases of HIV infection are estimated to boost the global HIV-associated lipodystrophy market growth during the forecast period.

For instance, according to the UNAIDS, a Joint United Nations Programme on HIV and AIDS, in 2022over 39.0 million individuals worldwide were living with HIV, more than 1.3 million individuals were newly infected with HIV and around 630 000 individuals died because of AIDS-related ailments. Moreover, according to the same source about 29.8 million individuals with AIDS were accessing antiretroviral therapy in 2022, and a sum of 85.6 million individuals were infected with HIV causing 40.4 million deaths from AIDS-related illnesses since the beginning of the epidemic.

Increasing Number of Initiatives to Fight Against HIV Burden

The increasing initiatives from governments to fight the growing burden of HIV infection cases and associated deaths are also contributing to the global market growth. For instnace, in May 2023, the National HIV/AIDS Strategy and the Ending the HIV Epidemic in the U.S. Initiative emphasized detecting people as shortly as possible and confirming the availability of considerable HIV testing modalities to sufficiently satisfy the requirements of inhabitants with an improved chance of transmission owing to a broad spectrum of social, economic, and demographic aspects including stigma, discrimination, etc.

Again, since the research exhibits that a steady residence is essential to the well-being of individuals living with HIV/AIDS, and influences better health effects and decreased transmission of the infection, the U.S. Department of Housing and Urban Development's (HUD) Office of HIV/AIDS Housing declared it over $13 million in Housing Opportunities for people with AIDS (HOPWA) Permanent Supportive Housing (PSH) Renewal and Replacement Grants, which aid with tenant-based rental service, substantiating assistance, and additional accommodation activities in December 2022.

Large Expenses of HIV-Associated Lipodystrophy Therapy

The large expenses of HIV-associated lipodystrophy therapy is expected to hamper HIV-associated Lipodystrophy market growth in the forecast period. For instance, the Sculptra(injectable poly-L-lactic acid, New-Fill) therapy is the foremost facial filler authorized in the US for HIV-related lipoatrophy which costs roughly $500 to $1000 per vial in the US excluding fees for anesthesia or the surgical facility. Radiesse (calcium hydroxylapatite) is also FDA-approved for facial lipoatrophy in individuals living with HIV.

Radiesse includes synthetic calcium hydroxylapatite, a substance discovered in bones and teeth that promotes the body's production of collagen, the therapy costs approximately $600 to $800 per vial in the US. Similarly, the autologous fat transplant procedure also anointed 'fat-grafting' or fat transfer, costs several thousand dollars and the collagen (CosmoDerm, CosmoPlast) cost per treatment in the US varies from $300-$900, and therapies last for three to six months, requiring repetative session.

Gaps in HIV Anti Retroviral Therapy

The gaps in HIV ART therapy are also expected to slow the global market growth during the forecast period. For instnace, in 2015, the World Health Organization (WHO) modified multinational HIV policies and approved a "Treat All" policy, which withdrew CD4-based clinical staging measures for antiretroviral therapy (ART) initiation and extended ART eligibility for children.

While, the "Treat All" policy called for raised equity in HIV therapy, between 2010 and 2020, the pediatric ART range increased threefold, leaping from 16% to 54%. However, pediatric coverage yet invariably crawled after adult ART coverage, which leaped from 26% in 2010 to 74% in 2020. Meanwhile, AIDS-related casualties fell by over half, going from 240,000 to 99,000 over a period of 10 years.

Segment Analysis

The global HIV-associated lipodystrophy market is segmented based on type, route of administration, distribution channel and region.

The Drug Treatment Type is Expected to Dominate the Market

The availability of specific drug treatment for HIV-associated lipodystrophy and the growing prevalence of diabetes cases in HIV-infected patients are expected to boost the segment growth in the forecast period. For instance, EGRIFTA SV is an FDA-authorized injectable prescription medicine utilized to lower extra abdominal fat in adult individuals living with HIV and lipodystrophy. EGRIFTA SV is a growth hormone-releasing factor (GHRF) analog.

Moreover, according to Georgia University, Diabetes mellitus is one of the chronic comorbidities found in individuals with HIV. Studies have reported changes in glucose homeostasis or fat redistribution in HIV-infected patients. Identified risk factors associated with the development of diabetes in pers ns without HIV are the same as those in PLWHIV, including higher triglyceride, older age, obesity, genetics, and hypertension. Further, HIV and some HAART medicines may also increase the chance of acquiring diabetes or developing it at a younger age. A 2021 investigation assesses that over 15 percent of individuals with HIV have diabetes.

Geographical Penetration

Increasing Number of HIV Infections Cases in North America

Owing to the increasing number of HIV infections, government funding, and awareness initiatives are boosting the regional market growth during the forecast period. For instance, a fresh investigation from the Centers for Disease Control and Prevention demonstrates that the number of individuals obtaining lifesaving HIV therapy via PEPFAR has risen 300-fold in just 20 years, from 2004 to 2022. The statistics of individuals obtaining HIV antiretroviral therapy (ART) via PEPFAR grew from merely 66,500 people in 2004, the year after PEPFAR was introduced, to over 20 million individuals in 2022.

Further, in April 2023, the Health Resources and Services Administration (HRSA), an association of the U.S. Department of Health and Human Services (HHS), rewarded over $147 million to 49 recipients to extend the Ending the HIV Epidemic in the U.S. (EHE) initiative, which is an aspect of the Biden-Harris Administration's continued measures to decrease the number of recent HIV infections in the United States by at least 90% by 2030. This funding is expected to support states and metropolitan areas with the highest levels of HIV transmission to link individuals with HIV to elementary care, aid, therapy, asset training, and other aids for these jurisdictions.

Also, the Southern HIV/AIDS Awareness Day (SHAAD) is a day that people, societies, and associations can join to summon awareness of the disproportionate number of individuals living with HIV in the South. SHAAD is a chance to deliver individuals in the South with HIV testing and connection to HIV medical care if required, instruction on HIV prevention, including methods to stop HIV stigma and other HIV-related care aids.

COVID-19 Impact Analysis

The pandemic disturbed the global healthcare system with disturbances in diagnosis, treatments, and research activities for other conditions which negatively impacted the overall healthcare market growth including HIV-associated lipodystrophy. However, as HIV-associated lipodystrophy was believed to be among the post-COVID-19 complications leading increase in diagnosis and treatment demands having a positive impact on the market growth.

Testing is the foremost method to learn if a person has been infected with SARS-CoV-2. Individuals with HIV were advised to instantly reach their healthcare provider if they tested positive for COVID-19. Individuals with HIV were suggested to persist in taking their HIV medications as specified. The Centers for Disease Control and Prevention (CDC) advised that individuals with HIV who were qualified should get a COVID-19 vaccine primary dose (also known as the initial dose), and a booster dose, regardless of viral burden or CD4 T lymphocyte cell count. Thus, the pandemic is estimated to hold an intermediate impact over the global market.

By Type

  • Drug Treatment
    • Anabolism Modulators
    • Growth Hormones
    • Anabolic Steroids
    • Metformin
    • Thiazolidinediones
    • Others
  • Cosmetic Corrective Treatment
    • Lipotherapy
    • Lipoaccumulation
    • Dermal Fillers
    • Autologous Fat Transplant
    • Other

By Route of Administration

  • Oral
  • Injectables
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In August 2022, the European Commission authorized lenacapavir for treatment-experienced individuals with multidrug-resistant HIV who cannot otherwise create a thoroughly suppressive regimen.
  • In August 2023, global pharma major Lupin Limited acquired the diabetes brands ONDERO and ONDERO MET, from Boehringer Ingelheim, including the trademark rights associated with these brands.

Competitive Landscape

The major global players in the market include: Theratechnologies Inc., Amryt Pharmaceuticals, Inc., Fawn Incorporation, Abbott Healthcare Solutions, Lupin Pharmaceuticals, Inc., Pfizer Inc., Bayer Inc., AstraZeneca, Novartis Pharmaceuticals Corporation, AbbVie, Galderma Laboratories, L.P. and GlaxoSmithKline among others.

Why Purchase the Report?

  • To visualize the global HIV-associated lipodystrophy market segmentation based on type, route of administration, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of HIV-associated lipodystrophy market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key product of all the major players.

The global HIV-associated lipodystrophy market report would provide approximately 61 tables, 58 figures and 186 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Distribution Channel
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Growing Prevalence of HIV Drive the Market Growth
      • 4.1.1.2. Increasing Number of Initiatives to Fight Against HIV Burden
    • 4.1.2. Restraints
      • 4.1.2.1. Large Expenses of HIV-Associated Lipodystrophy Therapy
      • 4.1.2.2. Gaps in HIV Anti-Retroviral Therapy
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Patent Analysis
  • 5.6. Distribution Channel Trend
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Drug Treatment*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Anabolism Modulators
    • 7.2.4. Growth Hormones
    • 7.2.5. Anabolic Steroids
    • 7.2.6. Metformin
    • 7.2.7. Thiazolidinediones
    • 7.2.8. Others
  • 7.3. Cosmetic Corrective Treatment
    • 7.3.1. Lipotherapy
    • 7.3.2. Lipoaccumulation
    • 7.3.3. Dermal Fillers
    • 7.3.4. Autologous Fat Transplant
    • 7.3.5. Other

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Ophthalmology Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Injectables
  • 8.4. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Retail Pharmacies
  • 9.4. Online Pharmacies

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Theratechnologies Inc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Amryt Pharmaceuticals, Inc.
  • 12.3. Fawn Incorporation
  • 12.4. Abbott Healthcare Solutions
  • 12.5. Lupin Pharmaceuticals, Inc.
  • 12.6. Pfizer Inc.
  • 12.7. Bayer Inc.
  • 12.8. Novartis Pharmaceuticals Corporation
  • 12.9. AstraZeneca
  • 12.10. GlaxoSmithKline
  • 12.11. AbbVie
  • 12.12. Galderma Laboratories, L.P.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us